Beranda › Neuroblastoma › California
Uji klinis Neuroblastoma di California
14 studi untuk Neuroblastoma mencari peserta di lokasi di California.
Kota di California
- San Francisco7 studi
- Los Angeles7 studi
- Mountain View5 studi
- Oakland5 studi
- San Diego5 studi
- Orange3 studi
Teks studi resmi (Bahasa Inggris)
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
- Kaiser Permanente Downey Medical Center, Downey
- City of Hope Comprehensive Cancer Center, Duarte
- Loma Linda University Medical Center, Loma Linda
- dan 13 lainnya
Menerima pesertaFase 3
Hingga usia 30 · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT06172296MCT for the Harvard/UCSF ROBIN Center
- University of California, San Francisco, San Francisco
Menerima peserta
Semua usia · Semua jenis kelamin · Diperbarui 1 Okt 2026 · NCT06000787Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
- Children's Hospital Los Angeles ( Site 1006), Los Angeles
Menerima pesertaFase 1/2
6 Months – 25 Years · Semua jenis kelamin · Diperbarui 17 Sep 2026 · NCT06395103Pediatric Precision Laboratory Advanced Neuroblastoma Therapy
- UCSF Benioff Children's Hospital Oakland, Oakland
- Rady Children's Hospital, San Diego
Menerima pesertaFase 2
Hingga usia 22 · Semua jenis kelamin · Diperbarui 4 Sep 2026 · NCT02559778Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
- UCSF Benioff Children's Hospital Oakland, Oakland
- Rady Children's Hospital, San Diego
Menerima pesertaFase 1/2
Hingga usia 30 · Semua jenis kelamin · Diperbarui 3 Sep 2026 · NCT06541262Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
- Kaiser Permanente Downey Medical Center, Downey
- Loma Linda University Medical Center, Loma Linda
- Children's Hospital Los Angeles, Los Angeles
- dan 9 lainnya
Menerima pesertaFase 3
365 Days – 30 Years · Semua jenis kelamin · Diperbarui 25 Agu 2026 · NCT03126916Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- Children's Hospital Los Angeles, Los Angeles
- Children's Hospital of Orange County, Orange
- UCSF Medical Center-Mission Bay, San Francisco
Menerima pesertaFase 1/2
12 Months – 30 Years · Semua jenis kelamin · Diperbarui 25 Agu 2026 · NCT04851119Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma
- UCSF Benioff Children's Hospital Oakland, Oakland
- Rady Children's Hospital, San Diego
Menerima pesertaFase 2
12 Months – 21 Years · Semua jenis kelamin · Diperbarui 12 Agu 2026 · NCT05489887SPEARHEAD-3 Pediatric Study
- Stanford University, Palo Alto
Menerima pesertaFase 1/2
Usia 2 hingga 21 · Semua jenis kelamin · Diperbarui 11 Agu 2026 · NCT05642455PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors
- Cedars-Sinai Medical Center, Los Angeles
- University of California, San Francisco, San Francisco
Menerima pesertaFase 1/2
Usia 1 hingga 30 · Semua jenis kelamin · Diperbarui 22 Jul 2026 · NCT06721689NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial
- Children's Hospital Los Angeles, Los Angeles
- UCSF Benioff Children's Hospital, San Francisco
Menerima pesertaFase 2
Usia 1 hingga 31 · Semua jenis kelamin · Diperbarui 20 Jul 2026 · NCT06450041Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma
- Lucille Packard Children's Hospital Stanford, Palo Alto
Menerima pesertaFase 1/2
12 Months – 30 Years · Semua jenis kelamin · Diperbarui 19 Mei 2026 · NCT04901702Autologous B7-H3 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Solid Tumors
- Stanford University, Palo Alto
Menerima pesertaFase 1
Usia 2 hingga 30 · Semua jenis kelamin · Diperbarui 7 Mei 2026 · NCT06500819Neuroblastoma Biology Study
- Children's Hospital Los Angeles, Los Angeles
- UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco
Menerima pesertaStudi observasional
31 Days – 99 Years · Semua jenis kelamin · Diperbarui 23 Mar 2026 · NCT01587300Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.